Showing results (591-600 of 739) with videos related to

Sort By:
Pageof 74
Journal of Hematology & Oncology|October 22, 2015
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Todd A Alonzo, Chelsea J Gudgeon, et al.
Vaccine|April 9, 1999
Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adultsE B Walter, R B Hornick, G A Poland, et al.
Haematologica|January 28, 2017
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysisSarah A Buckley, Brent L Wood, Megan Othus, et al.
Leukemia|April 27, 2022
Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignanciesGeorge S Laszlo, Johnnie J Orozco, Allie R Kehret, et al.
Clinical Pharmacokinetics|January 12, 2023
Population Pharmacokinetics of Piperacillin/Tazobactam Across the Adult LifespanMarion Hemmersbach-Miller, Stephen J Balevic, Patricia L Winokur, et al.
Leukemia|February 16, 2021
Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapyColin D Godwin, George S Laszlo, Salvatore Fiorenza, et al.
British Journal of Haematology|December 11, 2012
Increased leucocyte apoptosis in transfused β-thalassaemia patientsPatrick B Walter, John Porter, Patricia Evans, et al.
Der Nervenarzt|July 30, 2015
[Provision of assistive devices in amyotrophic lateral sclerosis. Analysis of 3 years case management in an internet-based supply network]A Funke, T Grehl, J Großkreutz, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene TherapyFlorence Borot, Olivier Humbert, Gregory A Newby, et al.
Haematologica|May 28, 2026
Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysisJesse M Tettero, Mei-Jie Zhang, Wentong Liu, et al.
Pageof 74